Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women

Laura D Bilek, Nancy L Waltman, Joan M Lappe, Kevin A Kupzyk, Lynn R Mack, Diane M Cullen, Kris Berg, Meghan Langel, Melissa Meisinger, Ashlee Portelli-Trinidad, Molly Lang, Laura D Bilek, Nancy L Waltman, Joan M Lappe, Kevin A Kupzyk, Lynn R Mack, Diane M Cullen, Kris Berg, Meghan Langel, Melissa Meisinger, Ashlee Portelli-Trinidad, Molly Lang

Abstract

Background: In the United States, over 34 million American post-menopausal women have low bone mass (osteopenia) which increases their risk of osteoporosis and fractures. Calcium, vitamin D and exercise are recommended for prevention of osteoporosis, and bisphosphonates (BPs) are prescribed in women with osteoporosis. BPs may also be prescribed for women with low bone mass, but are more controversial due to the potential for adverse effects with long-term use. A bone loading exercise program (high-impact weight bearing and resistance training) promotes bone strength by preserving bone mineral density (BMD), improving bone structure, and by promoting bone formation at sites of mechanical stress.

Methods/design: The sample for this study will be 309 women with low bone mass who are within 5 years post-menopause. Subjects are stratified by exercise history (≥2 high intensity exercise sessions per week; < 2 sessions per week) and randomized to a control or one of two treatment groups: 1) calcium + vitamin D (CaD) alone (Control); 2) a BP plus CaD (Risedronate); or 3) a bone loading exercise program plus CaD (Exercise). After 12 months of treatment, changes in bone structure, BMD, and bone turnover will be compared in the 3 groups. Primary outcomes for the study are bone structure measures (Bone Strength Index [BSI] at the tibia and Hip Structural Analysis [HSA] scores). Secondary outcomes are BMD at the hip and spine and serum biomarkers of bone formation (alkaline phosphase, AlkphaseB) and resorption (Serum N-terminal telopeptide, NTx). Our central hypothesis is that improvements in bone strength will be greater in subjects randomized to the Exercise group compared to subjects in either Control or Risedronate groups.

Discussion: Our research aims to decrease the risk of osteoporotic fractures by improving bone strength in women with low bone mass (pre-osteoporotic) during their first 5 years' post-menopause, a time of rapid and significant bone loss. Results of this study could be used in developing a clinical management pathway for women with low bone mass at their peak period of bone loss that would involve lifestyle modifications such as exercises prior to medications such as BPs.

Trial registration: Clinicaltrials.gov NCT02186600 . Initial registration: 7/7/2014.

Keywords: Bone mineral density; Bone structure; Bone-loading exercises; Calcium and vitamin D; Low bone mass; Osteoporosis; Postmenopausal women; Risedronate.

Figures

Fig. 1
Fig. 1
Experimental design and flow chart

References

    1. Wright N, Looker A, Saag K, et al. The recent prevalence of osteoporosis and low bone mass based on the bone mineral density at the femoral neck or lumbar spine in the united states. J Bone Miner Res. 2014;29 (11): 2520-26.
    1. Borgström F, Lekander I, Ivergård M, et al. The international costs and utilities related to osteoporotic fractures study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporosis Int. 2013;24(3):811–823. doi: 10.1007/s00198-012-2240-2.
    1. Cosman F, De Beur S, LeBoff M, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25(10):2359–2381. doi: 10.1007/s00198-014-2794-2.
    1. Lee Y, Lee Y, Ha Y, Koo K. Five-year relative survival of patients with osteoporotic hip fracture. J Clin Endocrinol Metab. 2013;99(1):97–100. doi: 10.1210/jc.2013-2352.
    1. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243–1251. doi: 10.1093/gerona/glt093.
    1. Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the united states. Mayo Clin Proc. 2015;90(1):53–62. doi: 10.1016/j.mayocp.2014.09.011.
    1. Frisoli A, Jr, Chaves PH, Ingham SJ, Fried LP. Severe osteopenia and osteoporosis, sarcopenia, and frailty status in community-dwelling older women: results from the women’s health and aging study (WHAS) II. Bone. 2011;48(4):952–957. doi: 10.1016/j.bone.2010.12.025.
    1. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Mineral Res. 2000;15:1965–1973. doi: 10.1359/jbmr.2000.15.10.1965.
    1. Prentice R, Pettinger M, Jackson R, et al. Health risks and benefits from calcium and vitamin D supplementation: women’s health initiative clinical trial and cohort study. Osteoporosis Int. 2013;24(2):567–580. doi: 10.1007/s00198-012-2224-2.
    1. Roux C, Binkley N, Boonen S, et al. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94(2):153–157. doi: 10.1007/s00223-013-9763-1.
    1. McClung MR, Benhamou C, Man Z, et al. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcif Tissue Int. 2013;92(1):59–67. doi: 10.1007/s00223-012-9668-4.
    1. Uusi-Rasi K, Kannus P, Cheng S, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone. 2003;33(1):132–143. doi: 10.1016/S8756-3282(03)00082-6.
    1. Anitha D, Kim K, Lim S, Lee T. Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: A 3-year follow-up finite element study in risedronate-treated women. Osteoporosis Int. 2013;24(12):3043–3051. doi: 10.1007/s00198-013-2424-4.
    1. Angthong C, Angthong W. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. J Med Assoc Thai. 2011;94(Suppl 7):S214–S220.
    1. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2014;29(1):1–23. doi: 10.1002/jbmr.1998.
    1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;3(90):1294–1301. doi: 10.1210/jc.2004-0952.
    1. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897–1899. doi: 10.1210/jc.2005-0057.
    1. Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;41:378–385. doi: 10.1016/j.bone.2007.04.198.
    1. Schneider J. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman or long-term alendronate. Geriatrics. 2006;61:31–33.
    1. Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014;174(7):1126–1134. doi: 10.1001/jamainternmed.2014.1232.
    1. Lenard L. Bisphosphonates: Bone strengtheners or bone hardeners? Townsend Letter: The Examiner of Alternative Medicine. 2009;312:76–81.
    1. Martyn-St James M, Carroll S. A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes. Br J Sports Med. 2009;43(12):898–908. doi: 10.1136/bjsm.2008.052704.
    1. Kido S, Kuriwaka-Kido R, Umino-Miyatani Y, et al. Mechanical stress activates smad pathway through PKCdelta to enhance interleukin-11 gene transcription in osteoblasts. PLoS One. 2010;5(9):e13090. doi: 10.1371/journal.pone.0013090.
    1. Kemmler W, Engelke K, Lauber D, Weineck J, Hensen J, Kalender WA. Exercise effects on fitness and bone mineral density in early postmenopausal women: 1-year EFOPS results. Med Sci Sports Exerc. 2002;34(12):2115–2123. doi: 10.1097/00005768-200212000-00038.
    1. Linnebur SA, Vondracek SF, Vande Griend JP, Ruscin JM, McDermott MT. Prevalence of vitamin D insufficiency in elderly ambulatory outpatients in denver, colorado. Am J Geriatr Pharmacother. 2007;5(1):1–8. doi: 10.1016/j.amjopharm.2007.03.005.
    1. Lappe JM, Davies KM, Travers-Gustafson D, Heaney RP. Vitamin D status in a rural postmenopausal female population. J Am Coll Nutr. 2006;25(5):395–402. doi: 10.1080/07315724.2006.10719551.
    1. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007;85(3):649–650.
    1. Waltman NL, Twiss JJ, Ott CD, et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos Int. 2010;21(8):1361–1369. doi: 10.1007/s00198-009-1083-y.
    1. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. BMD-MN study group. J Clin Endocrinol Metab. 2000;85(5):1895–1900.
    1. Peppone LJ, Mustian KM, Janelsins MC, et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer. 2010;10(3):224–229. doi: 10.3816/CBC.2010.n.030.
    1. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Jones LW. Exercise motivation and adherence in cancer survivors after participation in a randomized controlled trial: an attribution theory perspective. Int J Behav Med. 2004;11(1):8–17. doi: 10.1207/s15327558ijbm1101_2.
    1. Knobf MT, Insogna K, DiPietro L, Fennie K, Thompson AS. An aerobic weight-loaded pilot exercise intervention for breast cancer survivors: bone remodeling and body composition outcomes. Biol Res Nurs. 2008;10(1):34–43. doi: 10.1177/1099800408320579.
    1. Bandura A. Self-efficacy: The exercise of control. New York: W.H. Freeman & Co; 1997.
    1. Rogers L, Markwell S, Hopkins-Price P, et al. Reduced barriers mediated physical activity maintenance among breast cancer survivors. J Sport Exerc Psychol. 2011;33(2):235. doi: 10.1123/jsep.33.2.235.
    1. Rogers L, Fogleman A, Verhulst S, Malone J, Robbs R, Robbins K. Refining measurement of social cognitive theory factors associated with exercise adherence in head & neck patients. J Psychosoc Oncol. 2015;33(5):467–87.
    1. Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014;18(11):1–180. doi: 10.3310/hta18110.
    1. Bonnick SL. Dual-energy x-ray absorptiometry: interpreting reports and serial measurements. Clin Obstet Gynecol. 2013;56(4):677–685. doi: 10.1097/GRF.0b013e3182a8240c.
    1. McCloskey EV, Odén A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int. 2015;96(6):500–509. doi: 10.1007/s00223-015-9980-x.
    1. Ohnaru K, Sone T, Tanaka K, et al. Hip structural analysis: A comparison of DXA with CT in postmenopausal japanese women. Springerplus. 2013;2:331-1801-2-331. eCollection 2013.
    1. Garnero P. Biochemical markers of bone turnover. 1. Philadelphia, PA: Mosby; 2006.
    1. Pate D. Long-term bisphosphonate use and increased fracture risk. Dynamic Chiropract. 2010;28(13):5p.
    1. Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632–637. doi: 10.1016/S0025-6196(11)60752-0.
    1. Mashiba T, Turner CH, Hirano T, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone. 2001;29(3):271–278. doi: 10.1016/S8756-3282(01)00575-0.
    1. van der Linden JC, Weinans H. Effects of microarchitecture on bone strength. Curr Osteoporos Rep. 2007;5(2):56–61. doi: 10.1007/s11914-007-0003-3.
    1. Akhter MP, Lappe JM, Davies KM, Recker RR. Transmenopausal changes in the trabecular bone structure. Bone. 2007;41(1):111–116. doi: 10.1016/j.bone.2007.03.019.
    1. Vainionpaa A, Korpelainen R, Sievanen H, Vihriala E, Leppaluoto J, Jamsa T. Effect of impact exercise and its intensity on bone geometry at weight-bearing tibia and femur. Bone. 2007;40(3):604–611. doi: 10.1016/j.bone.2006.10.005.
    1. Heinonen A, Mäntynen J, Kannus P, et al. Effects of high-impact training and detraining on femoral neck structure in premenopausal women: a hip structural analysis of an 18-month randomized controlled exercise intervention with 3.5-year follow-up. Physiother Can. 2012;64(1):98–105. doi: 10.3138/ptc.2010-37.
    1. Eastell R, Bainbridge P. Bone turnover markers: Their place in the investigation of osteoporsis. In: Orwoll ES, Bliziotes M, editors. Osteoporosis: Pathophysiology and clinical management. Totowa, New Jersey: Humana Press; 2003. pp. 185–198.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera